Pércio S. Gulko, MD, Named Chief of Rheumatology for the Mount Sinai Health System
The Mount Sinai Health System has announced Pércio S. Gulko, MD, as Chief of the Division of Rheumatology in the Samuel Bronfman Department of Medicine. An expert in rheumatoid arthritis and author of over sixty leading peer-reviewed publications, Dr. Gulko will play a key role in advancing patient care, expanding research and developing comprehensive and innovative treatments for patients suffering from rheumatological disorders.
“We are pleased to have a physician of Dr. Gulko’s caliber join the Division of Rheumatology at Mount Sinai,” said Barbara Murphy, MD, Chair of the Samuel Bronfman Department of Medicine and Dean of Clinical Integration and Population Health at the Icahn School of Medicine at Mount Sinai for The Mount Sinai Health System. “He will lead our team in continuing to provide exceptional patient care while paving the way for research and scientific advances in this critically important field of medicine.”
Dr. Gulko’s research has focused on the identification and characterization of new genes implicated in the regulation of disease severity and joint damage in rheumatoid arthritis. He has received numerous grants from the National Institutes of Health, and has lectured both nationally and internationally. Dr. Gulko serves on the Editorial Board of Genes and Immunity and Physiological Genomics, and is a member of the American College of Rheumatology.
In his new position, Dr. Gulko will lead a team of highly-trained, multidisciplinary experts in offering specialized care for conditions such as psoriatic arthritis, rheumatoid arthritis, lupus, and Sjogren syndrome, as well as osteoarthritis, inflammatory muscle disease, amyloidosis, and related conditions under a new Arthritis Center of Excellence. Dr. Gulko plans to expand Mount Sinai’s research and clinical trials to better understand rheumatologic diseases and identify new treatments to improve patient care.
“I am honored to work with such an esteemed group of physicians at a world-renowned institution," said Dr. Gulko. “Together, we will build upon the division’s existing success by combining breakthrough research and extraordinary patient care for those who suffer from rheumatologic diseases. We will provide comprehensive rheumatologic care.”
Dr. Gulko joins Mount Sinai from North Shore-LIJ in Manhasset, New York where he served as Professor and Director of the Laboratory of Experimental Rheumatology at the Center for Genomics and Human Genetics at the Feinstein Institute for Medical Research. He was also a Professor of Molecular Medicine at Hofstra University and an Attending Physician in the Division of Rheumatology at North Shore University Hospital.
Dr. Gulko completed his medical degree, internship and clinical fellowship in Rheumatology at the Universidade Federal do Rio Grande do Sul. Porto Alegre in Brazil. He came to the United States as a research fellow in the Division of Rheumatology at the University of Alabama at Birmingham, and later completed his residency in Internal Medicine at the Medical College of Georgia in Augusta. He also completed a rheumatology fellowship at the National Institutes of Health, and was a faculty member at the Divisions of Autoimmune and Molecular Disease and Rheumatology at Columbia University’s College of Physicians and Surgeons before joining the Feinstein Institute.
About the Mount Sinai Health System
Mount Sinai Health System is one of the nation’s leading integrated academic health systems and one of the largest in the New York metropolitan area. Its comprehensive system includes seven hospitals, more than 400 outpatient practices, over 600 research and clinical laboratories, the Icahn School of Medicine at Mount Sinai, the Graduate School of Biomedical Sciences, and the Mount Sinai Phillips School of Nursing. Together, the Health System comprises approximately 48,000 employees, more than 9,000 physicians, and 8,600 nurses.
As a leading learning health system, Mount Sinai combines clinical expertise with scientific discovery to improve patient care while training the next generation of health care and biomedical leaders. The Health System provides care across every stage of life, from prenatal care through geriatrics, while advancing personalized medicine through artificial intelligence, data science, and biomedical research.
Mount Sinai is consistently recognized among the nation’s leading academic health systems for patient care, research, and education. The Mount Sinai Hospital is ranked No. 1 in New York by Newsweek and No. 5 on the magazine’s World’s Best Hospitals list. The Icahn School of Medicine at Mount Sinai ranks No. 11 among U.S. medical schools and No. 1 among freestanding medical schools for National Institutes of Health funding, reflecting the strength of its scientific enterprise and leadership in biomedical research.